神州细胞工程有限公司 (Sinocelltech) is a biotech firm founded in 2007 with the slogan "Pioneering accessible and affordable biological medicines through advanced protein and antibody technologies." The company is focused on the development and production of recombinant proteins, monoclonal antibodies, and vaccines. Sinocelltech has established platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. The organization's mission is to make life-saving biological medicines accessible to the general public by continually enhancing process and manufacturing technologies, ultimately reducing the cost of product development and production.
In May 2017, Qiming Venture Partners made a CNY200.00M Series A investment in Sinocelltech, aligning with the company's goal of expanding accessibility to vital biological medicines. Sinocelltech operates in the Biotechnology, Health Care, Manufacturing, and Medical Devices industries, positioning itself at the forefront of innovative biotechnological advancements. While the company's headquarters are not specified, its focus on cutting-edge biological medicines and significant investment from Qiming Venture Partners indicates a promising trajectory in the biotech sector.
